All Stories

  1. Endosome-phagophore linking assemblies for the degradation of membrane/extracellular proteins
  2. Discovery of New N -H Aporphine Derivatives As Brain-Penetrant G q -Biased 5-HT 2C Receptor Agonists an...
  3. Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development
  4. Selective recognition memory impairment in mitochondrial hydroxylase Clk1 mutant mice, rescued by antipsychotics
  5. Serum amyloid A drive microglia shift to a resolving phenotype through Nrf2
  6. Biomimetic membrane-coated nanoparticles specially permeate the inflammatory blood-brain barrier to deliver plasmin therapy for brain metastases
  7. Psychotic Illness as a Disorder of Subtle, Whole-body Maldevelopment: Challenges and Opportunities for Drug Discovery
  8. Polo-like kinase 2 promotes microglial activation via regulation of the HSP90α/IKKβ pathway
  9. Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
  10. KCTD proteins regulate morphine dependence via heterologous sensitization of adenylyl cyclase 1 in mice
  11. Suppressing Wnt signaling of the blood‒tumor barrier to intensify drug delivery and inhibit lipogenesis of brain metastases
  12. The NTE domain of PTENα/β promotes cancer progression by interacting with WDR5 via its SSSRRSS motif
  13. Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood–tumor barrier for boosted brain tumor therapy
  14. The classical D1 dopamine receptor antagonist SCH23390 is a functional sigma-1 receptor allosteric modulator
  15. Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis
  16. Targeted to neuronal organelles for CNS drug development
  17. Identifying the core concepts of pharmacology education: A global initiative
  18. Sigma-1 receptor-regulated efferocytosis by infiltrating circulating macrophages/microglial cells protects against neuronal impairments and promotes functional recovery in cerebral ischemic stroke
  19. A small molecule antagonist of SMN disrupts the interaction between SMN and RNAP II
  20. Dopamine D1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the AMPK/FOXO3A pathway
  21. Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects
  22. Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice
  23. Inhibition of neuroinflammation by MIF inhibitor 3-({[4-(4-methoxyphenyl)-6-methyl-2-pyrimidinyl]thio}1methyl)benzoic acid (Z-312)
  24. Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection
  25. Discovery of novel MIF inhibitors that attenuate microglial inflammatory activation by structures-based virtual screening and in vitro bioassays
  26. Early glycolytic reprogramming controls microglial inflammatory activation
  27. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach
  28. Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases
  29. PHLDA1 promotes microglia-mediated neuroinflammation via regulating K63-linked ubiquitination of TRAF6
  30. Protective Effect of Metformin against Hydrogen Peroxide-Induced Oxidative Damage in Human Retinal Pigment Epithelial (RPE) Cells by Enhancing Autophagy through Activation of AMPK Pathway
  31. Knockdown of milk‐fat globule EGF factor‐8 suppresses glioma progression in GL261 glioma cells by repressing microglial M2 polarization
  32. Emerging novel approaches to drug research and diagnosis of Parkinson’s disease
  33. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson’s disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin
  34. C9orf72 associates with inactive Rag GTPases and regulates mTORC1‐mediated autophagosomal and lysosomal biogenesis
  35. Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond
  36. FoxO3a suppresses neuropeptide W expression in neuronal cells and in rat hypothalamus and its implication in hypothalamic-pituitary-adrenal (HPA) axis
  37. Absence of TRIM32 Leads to Reduced GABAergic Interneuron Generation and Autism-like Behaviors in Mice via Suppressing mTOR Signaling
  38. D2 receptor-mediated miRNA-143 expression is associated with the effects of antipsychotic drugs on phencyclidine-induced schizophrenia-related locomotor hyperactivity and with Neuregulin-1 expression in mice
  39. The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway
  40. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases
  41. Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge
  42. Emerging and evolving concepts in the pathobiology and treatment of psychosis
  43. Dysregulation of miRNA and its potential therapeutic application in schizophrenia
  44. Macrophage migration inhibitory factor (MIF) inhibitor, Z-590 suppresses cartilage destruction in adjuvant-induced arthritis via inhibition of macrophage inflammatory activation
  45. miRNA-3473b contributes to neuroinflammation following cerebral ischemia
  46. Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation
  47. Activation of AMPK/mTORC1-Mediated Autophagy by Metformin Reverses Clk1 Deficiency-Sensitized Dopaminergic Neuronal Death
  48. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies
  49. Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance
  50. Prediction of chemical biodegradability using computational methods
  51. Dihydromyricetin protects against cerebral ischemia/reperfusion injury via suppressing microglia-mediated neuroinflammation and activation of ERK1/2-CREB signaling pathway
  52. Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease through Comparative Structure-Based Virtual Screening
  53. Erratum: Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity
  54. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors
  55. Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming
  56. Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death
  57. GSK-3βInteracts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia
  58. Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory
  59. Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson’s Disease
  60. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity suppresses microglia-mediated inflammatory responses
  61. GSK-3β inhibitors reverse cocaine-induced synaptic transmission dysfunction in the nucleus accumbens
  62. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity
  63. Functional reversal of (−)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy
  64. LLDT-8 protects against cerebral ischemia/reperfusion injury by suppressing post-stroke inflammation
  65. Morphine-induced inhibition of Ca2+ -dependent d -serine release from astrocytes suppresses excitability of GABAergic neurons in the nucleus accumbens
  66. Accessible Method for the Development of Novel Sterol Analogues with Dipeptide-like Side Chains That Act as Neuroinflammation Inhibitors
  67. Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity
  68. Mice heterozygous for cathepsin D deficiency exhibit mania-related behavior and stress-induced depression
  69. MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation
  70. Structure–Activity Relationships and Anti-inflammatory Activities ofN-Carbamothioylformamide Analogues as MIF Tautomerase Inhibitors
  71. Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold
  72. Higher-Affinity Agonists of 5-HT1AR Discovered through Tuning the Binding-Site Flexibility
  73. Prefrontal cortex gates acute morphine action on dopamine neurons in the ventral tegmental area
  74. Protease Omi facilitates neurite outgrowth in mouse neuroblastoma N2a cells by cleaving transcription factor E2F1
  75. Neuropharmacological Actions of Metformin in Stroke
  76. Allosteric modulation of sigma-1 receptors elicits anti-seizure activities
  77. Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation
  78. Anti-inflammatory effects of glaucocalyxin B in microglia cells
  79. Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors
  80. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia
  81. Glial Pathology in Bipolar Disorder: Potential Therapeutic Implications
  82. Inhibition of Neuroinflammation by Synthetic Androstene Derivatives Incorporating Amino Acid Methyl Esters on Activated BV-2 Microglia
  83. Sigma-2 Receptor Ligands: Neurobiological Effects
  84. Absorption, Distribution, Metabolism, Excretion, and Toxicity Evaluation in Drug Discovery. 14. Prediction of Human Pregnane X Receptor Activators by Using Naive Bayesian Classification Technique
  85. Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors
  86. Rotenone impairs autophagic flux and lysosomal functions in Parkinson’s disease
  87. Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress
  88. A Computational Perspective on Drug Discovery and Signal Transduction Mechanism of Dopamine and Serotonin Receptors in the Treatment of Schizophrenia
  89. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles
  90. Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility
  91. CaMKKβ-Dependent Activation of AMP-Activated Protein Kinase Is Critical to Suppressive Effects of Hydrogen Sulfide on Neuroinflammation
  92. Structural manipulation on the catecholic fragment of dopamine D1 receptor agonist 1-phenyl-N-methyl-benzazepines
  93. Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference
  94. ChemInform Abstract: Topsendines A-F, New 3-Alkylpyridine Alkaloids from a Hainan Sponge Topsentia sp.
  95. (6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease
  96. Optimization of 6-Heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as Potent Adenosine A2AReceptor Antagonists for the Treatment of Parkinson’s Disease
  97. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke
  98. Effects of SKF83959 on the excitability of hippocampal CA1 pyramidal neurons: a modeling study
  99. Discovery of Novel Inhibitors Targeting the Macrophage Migration Inhibitory Factor via Structure-Based Virtual Screening and Bioassays
  100. Topsendines A–F, new 3-alkylpyridine alkaloids from a Hainan sponge Topsentia sp.
  101. Robo3.1A suppresses Slit-mediated repulsion by triggering degradation of Robo2
  102. Mutation of SLC35D3 Causes Metabolic Syndrome by Impairing Dopamine Signaling in Striatal D1 Neurons
  103. Synthesis of 5α-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: Discovery of a novel neuroinflammation inhibitor
  104. Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference
  105. Antiinflammatory Effects of Orientin-2″-O-Galactopyranoside on Lipopolysaccharide-Stimulated Microglia
  106. 1-O-Tigloyl-1-O-deacetyl-nimbolinin B Inhibits LPS-Stimulated Inflammatory Responses by Suppressing NF-κB and JNK Activation in Microglia Cells
  107. Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists
  108. Molecular Modeling of the 3D Structure of 5-HT1AR: Discovery of Novel 5-HT1AR Agonists via Dynamic Pharmacophore-Based Virtual Screening
  109. Postischemic Administration of a Potent PTEN Inhibitor Reduces Spontaneous Lung Infection Following Experimental Stroke
  110. Synthesis, preliminary pharmacological evaluation and receptor docking studies of 10-amino-3-methoxy-6,8,12,12a-tetrahydro-5H-thiazolo[4',5':4,5]pyrido[2,1-a]isoquinolin-2-ols as novel dopamine D1 receptor inhibitors
  111. Design, Synthesis, and Evaluation of Indolebutylamines as a Novel Class of Selective Dopamine D3 Receptor Ligands
  112. SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity
  113. Current developments of macrophage migration inhibitory factor (MIF) inhibitors
  114. Differential mechanisms underlying neuroprotection of hydrogen sulfide donors against oxidative stress
  115. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders
  116. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile
  117. Delayed administration of a PTEN inhibitor BPV improves functional recovery after experimental stroke
  118. CMYA5: a new potential substrate of Kcna3 in human heart
  119. SKF83959 Is a Potent Allosteric Modulator of Sigma-1 Receptor
  120. Methylphenidate Enhances NMDA-Receptor Response in Medial Prefrontal Cortex via Sigma-1 Receptor: A Novel Mechanism for Methylphenidate Action
  121. GABA Neurons in the Ventral Tegmental Area Responding to Peripheral Sensory Input
  122. Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: Selective inhibitors of dopamine D1 receptor
  123. Synthesis and antidepressant activity of arylalkanol-piperidine derivatives as triple reuptake inhibitors
  124. Generation and characterization of hD5 and C-terminal Mutant hD5m transgenic rats
  125. L166P mutant DJ-1 promotes cell death by dissociating Bax from mitochondrial Bcl-XL
  126. PSD-95 Interacts with Dopamine D1-Receptor: Functional Implication
  127. Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile
  128. SKF83959 suppresses excitatory synaptic transmission in rat hippocampus via a dopamine receptor-independent mechanism
  129. The Retardation of Myometrial Infiltration, Reduction of Uterine Contractility, and Alleviation of Generalized Hyperalgesia in Mice With Induced Adenomyosis by Levo-Tetrahydropalmatine (l-THP) and Andrographolide
  130. Further SAR study on 11-O-substituted aporphine analogues: Identification of highly potent dopamine D3 receptor ligands
  131. Levo-Tetrahydropalmatine Retards the Growth of Ectopic Endometrial Implants and Alleviates Generalized Hyperalgesia in Experimentally Induced Endometriosis in Rats
  132. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta
  133. Electrophysiological Effects of SKF83959 on Hippocampal CA1 Pyramidal Neurons: Potential Mechanisms for the Drug's Neuroprotective Effects
  134. l-Stepholidine-induced excitation of dopamine neurons in rat ventral tegmental area is associated with its 5-HT1A receptor partial agonistic activity
  135. Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels in the regulation of midbrain dopamine systems
  136. Activation of phosphatidylinositol-linked D1-like receptors increases spontaneous glutamate release in rat somatosensory cortical neurons in vitro
  137. l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
  138. Synthesis of Dihydrofuroaporphine Derivatives: Identification of a Potent and Selective Serotonin 5-HT1AReceptor Agonist
  139. Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand
  140. ‘Click’ D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity
  141. Activation of Phosphatidylinositol-Linked D1-Like Receptor Modulates FGF-2 Expression in Astrocytes via IP3-Dependent Ca2+ Signaling
  142. Arylbenzazepines Are Potent Modulators for the Delayed Rectifier K+ Channel: A Potential Mechanism for Their Neuroprotective Effects
  143. ChemInform Abstract: Dopamine D1Receptor Ligands: Where Are We Now and Where Are We Going
  144. PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation
  145. Dopamine D1receptor ligands: Where are we now and where are we going
  146. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons
  147. Limonoids from the Twigs and Leaves ofChukrasia tabularis
  148. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia
  149. Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D1 receptor activities
  150. Single Dose of Morphine Produced a Prolonged Effect on Dopamine Neuron Activities
  151. N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D2 and serotonin 5-HT1A receptor dual ligands
  152. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines
  153. The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study
  154. Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine
  155. Neuroprotective effects of atypical D1receptor agonist SKF83959 are mediated via D1receptor-dependent inhibition of glycogen synthase kinase-3β and a receptor-independent anti-oxidative action
  156. Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
  157. Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells
  158. Recent Development in Studies of Tetrahydroprotoberberines: Mechanism in Antinociception and Drug Addiction
  159. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
  160. Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine
  161. Requirement of PSD-95 for dopamine D1receptor modulating glutamate NR1a/NR2B receptor function
  162. l-Stepholidine increases the frequency of sEPSC via the activation of D1dopamine signaling pathway in rat prelimbic cortical neurons
  163. Estrogen-modulated frontal cortical CaMKII activity and behavioral supersensitization induced by prolonged cocaine treatment in female rats
  164. Modulation of Ca2+ signals by phosphatidylinositol-linked novel D1 dopamine receptor in hippocampal neurons
  165. The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm
  166. The role of the phosphatidyinositol-linked D dopamine receptor in the pharmacology of SKF83959
  167. Regulation of Cyclin-Dependent Kinase 5 and Calcium/Calmodulin-Dependent Protein Kinase II by Phosphatidylinositol-Linked Dopamine Receptor in Rat Brain
  168. Prenatal cocaine exposure alters glycogen synthase kinase-3β (GSK3β) pathway in select rabbit brain areas
  169. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain
  170. Inhibition of Protein Tyrosine/Mitogen-Activated Protein Kinase Phosphatase Activity Is Associated with D2 Dopamine Receptor Supersensitivity in a Rat Model of Parkinson's Disease
  171. Lithium regulates protein tyrosine phosphatase activity in vitro and in vivo
  172. Prenatal Exposure to Cocaine Disrupts D1ADopamine Receptor Function Via Selective Inhibition of Protein Phosphatase 1 Pathway in Rabbit Frontal Cortex
  173. The p38 Mitogen-Activated Protein Kinase Is Involved in Associative Learning in Rabbits
  174. Osteopontin Gene Regulation by Oscillatory Fluid Flow via Intracellular Calcium Mobilization and Activation of Mitogen-activated Protein Kinase in MC3T3-E1 Osteoblasts
  175. Mitogen-activated Protein Kinase p38 Mediates Regulation of Chondrocyte Differentiation by Parathyroid Hormone
  176. Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats
  177. Age-Associated Impairment in Brain MAPK Signal Pathways and the Effect of Caloric Restriction in Fischer 344 Rats
  178. D1Dopamine Receptor Agonists Mediate Activation of p38 Mitogen-Activated Protein Kinase and c-Jun Amino-Terminal Kinase by a Protein Kinase A-Dependent Mechanism in SK-N-MC Human Neuroblastoma Cells
  179. Platelet-Derived Growth Factor Stimulates Sodium-Dependent Pi Transport in Osteoblastic Cells via Phospholipase Cγ and Phosphatidylinositol 3′-Kinase
  180. Aluminum potentiates P(i) transport stimulation induced by fluoride in osteoblast-like cells
  181. Multimodal Detection and Recognition Performance of Sonar Operators